13 on the Billboard Hot 100, by far the highest-charting single from any of the four solo albums. It was released as a single and the song made it to No.
Frehley originally "scoffed" at the idea of the remake, but co-producer Eddie Kramer persisted. The song was a number nine hit in the UK, and subsequently reached number seven in Germany.Īce Frehley, best known as the lead guitarist of Kiss, recorded "New York Groove" for his first solo album, Ace Frehley, released in 1978 the album was released concurrently with solo albums from the other three Kiss members: Peter Criss, Gene Simmons and Paul Stanley. Additionally, TOPCAT still fails to demonstrate a significant reduction in death or all-cause hospitalizations.The British glam rock band Hello first recorded the song in 1975, for their debut album, Keeps Us Off the Streets.
HF hospitalization: 20.8% vs 24.5%, HR 0.82 (0.67-0.99) (NNT=28 over 3.3 years)Įxclusion of the Russia/Georgia participants renders the primary outcome statistically significant, but does not materially affect the effect estimate for the primary or secondary outcomes. Therefore, the results of the 'Americas' subgroup may be the most accurate reflection of the effect of spironolactone in HFpEF. This indicates that significantly more participants from Russia did not receive the study drug, and raises the potential of misconduct at these study sites. Russia/Georgia: 9.3% vs 8.4%, HR 1.10 (0.79-1.51)Ĭredibility of this subgroup effect has been increased by a substudy demonstrating that participants from Russia were far more likely than those from North America to have no detectable serum concentrations of spironolactone metabolites. Subgroup analysis: Primary outcome varied based on region (Americas vs Russia/Georgia, p<0.001 for interaction)Īmericas: Spironolactone 27.3% vs placebo 31.8%, HR 0.82 (0.69-0.98) (NNT=23) Unclear risk of bias: Loss-to-follow-up on vital status ~4%
TOPCAT BLINDS TRIAL
Low risk of bias characteristics: Randomized, allocation-concealed, double-blind trial analyzed using intention-to-treat population Heart transplant recipient or currently implanted LVADĬhronic pulmonary disease: Requiring home O2 or PO steroids, hospitalization for exacerbation within 12 months, or significant in the opinion of the investigator Infiltrative or hypertrophic obstructive cardiomyopathy (HoCM) Hemodynamically significant uncorrected primary valvular heart disease Heart failure with preserved ejection fraction (HFpEF):ĭefined as a clinical syndrome of signs & symptoms of HF with normal systolic function (LVEF >50% & LV end-diastolic volume index 45% (measured within 6 months prior to randomization & after any prior ACS)Ĭontrolled SBP (100 pg/mL (or N-terminal pro-BNP >360 pg/mL) within 30 days, not explained by another disease entity The label of "HFpEF" does not yet offer an actionable management plan. In this context, spironolactone remains useful for patients with HFpEF & resistant hypertension. Consistent with other "negative" studies in HFpEF, the results of TOPCAT supports the notion that patients with "HFpEF" should receive symptomatic treatment for HF, & interventions to reduce morbidity & mortality according to the underlying etiology. Spironolactone does not noticeably improve quality of life in HFpEF. Bottom line: In patients with HFpEF, spironolactone did not reduce the risk of death or hospitalization over 3.3 years. Spironolactone for heart failure with preserved ejection fraction.